Curative effect of interleukin 11 on chronic idiopathic thrombocytopenic purpura.
- Author:
Qiu-Rong ZHANG
1
;
De-Pei WU
;
Ling-Song CHEN
;
Ruo-Nan CAO
Author Information
1. Department of Hematology, The Second Affiliated Hospital, Xuzhou Medical Collage, Xuzhou 221006, China. xzqiurong@tom.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Chronic Disease;
Female;
Humans;
Interleukin-11;
blood;
therapeutic use;
Male;
Middle Aged;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic;
drug therapy;
Recombinant Proteins;
therapeutic use;
Treatment Outcome
- From:
Journal of Experimental Hematology
2006;14(1):176-178
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the circulating levels of IL-11 in the patients with chronic idiopathic thrombocytopenic purpura (CITP), and its significance, and to evaluate the curative effect of rhIL-11 on CITP. The level of IL-11 in patients with CITP was determined by ELISA before and after treatment, respectively. 1.5 mg of rhIL-11 were injected subcutaneously, once a day, continuously for 14 days as one course, treatment time 1 - 2 courses as total. The results showed that the higher blood IL-11 level was found in CITP patients than that in controls (P < 0.01) and during the course of treatment the number of platelets in peripheral blood of patients with CITP parallelled to the level of IL-11. The platelet counts were obviously increased in all CITP patients after rhIL-11 treatment. It is concluded that the serum level of IL-11 in patients is correlated to the number of platelets in patients. rhIL-11 can be used as an effective treatment for CITP.
